AliveDx Submits 510(k) Application for MosaiQ AiPlex® Multiplex Test for Systemic Connective Tissue Diseases AliveDx has submitted a 510(k) premarket notification to the FDA for its MosaiQ AiPlex® multiplex microarray aimed at diagnosing systemic connective tissue diseases efficiently.

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Multiplex Test for Systemic Connective Tissue Diseases #AliveDx #MosaiQ #AiPlex